Physician profile
Keith Campbell
NPI 1598899445
$14,303.50
in general payments reported to CMS, 2019-2025
33 companies · $2,341 in 2025
The $2,341 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,039 · 2022: $2,120 · 2023: $2,938 · 2024: $2,866 · 2025: $2,341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,033 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,033.40 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,928.08 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,632.00 | 2021-2025 | Rexulti, Abilify Mycite, Abilify Asimtufii |
| Alkermes, INC. | $1,424.81 | 2021-2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $854.08 | 2022-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $779.81 | 2021-2025 | Austedo Xr, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $778.82 | 2021-2025 | Caplyta |
| Lundbeck LLC | $745.09 | 2021-2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $622.49 | 2021-2024 | Jornay Pm |
| Corium, LLC | $618.10 | 2021-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $602.07 | 2021-2025 | Trintellix |
| Tris Pharma INC | $598.20 | 2021-2025 | Dyanavel Xr |
| Janssen Pharmaceuticals, INC | $509.27 | 2021-2025 | Spravato |
| Supernus Pharmaceuticals, INC. | $400.24 | 2021-2025 | Qelbree, Qelbree |
| Neos Therapeutics, LP | $374.80 | 2021-2025 | Adzenys Xr-Odt |
| Bausch Health US, LLC | $349.33 | 2021-2025 | Aplenzin |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $285.03 | 2022-2025 | Quviviq, Quviviq |
| Neurocrine Biosciences, INC. | $245.82 | 2022-2025 | Ingrezza |
| Eisai INC. | $233.91 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $217.07 | 2021 | |
| Vertical Pharmaceuticals, LLC | $196.71 | 2024-2025 | Relexxii |
| Noven Therapeutics, LLC | $163.10 | 2023-2025 | Xelstrym, Secuado |
| Vanda Pharmaceuticals INC. | $130.23 | 2021-2025 | Fanapt |
| Arbor Pharmaceuticals, INC. | $126.88 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $116.99 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $73.85 | 2021-2022 | |
| Adlon Therapeutics L.P. | $71.84 | 2021 | |
| Owp Pharmaceuticals, INC. | $56.54 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $46.38 | 2025 | Jornay Pm |
| Alfasigma USA, INC. | $34.95 | 2021 | |
| Sunovion Pharmaceuticals INC. | $29.99 | 2022 | |
| Avion Pharmaceuticals | $19.94 | 2023 | Methylphenidate Hydrochloride |
| Biogen, INC. | $19.52 | 2025 | Zurzuvae |
| E.R. Squibb & Sons, L.L.C. | $17.56 | 2025 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.